Flat-dose versus weight-based chemotherapy for CRS/HIPEC
Part of Cancer, Digestive system clinical trials.
This Phase 2 study compares two ways of dosing chemotherapy—one fixed (flat) dose versus dosing based on your weight—during CRS/HIPEC, a surgery-based treatment for certain cancers in the belly. It looks to see whether the dosing approach affects safety and effectiveness for people with peritoneal cancer spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these diagnoses: low-grade appendiceal mucinous neoplasm, pseudomyxoma peritonei, appendiceal cancer in the lining of the abdomen, or colorectal cancer in the lining of the abdomen
- Your overall function/strength is good enough (ECOG less than 3) to do study treatments
- Your cancer can be treated with surgery aimed to remove all visible tumor (grossly complete cytoreductive surgery)
- You’re expected to live more than 3 months and have blood, kidney, and liver function adequate for chemotherapy
- You can sign written informed consent and understand what the study involves
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at adding a heated medicine treatment (HIPEC with mitomycin C) during surgery to treat colon cancer that has spread to the lining of the abdomen (peritoneum). It aims to improve outcomes after surgeons remove visible tumor completely.
This trial tests a new way to deliver chemotherapy directly into the abdomen (called PIPAC) for people with cancer spread to the lining of the belly. It uses the drug mitomycin and is for patients who cannot have standard surgery or heated chemotherapy.
This study tests whether a specialized surgery called HIPEC (heat-treated chemotherapy placed in the belly) can improve outcomes for people with advanced stomach cancer that has reached the lining of the abdomen. It’s given after you’ve already had standard chemotherapy, aiming to better control disease in the belly.
This Phase 2 study tests whether a modified chemotherapy given inside the abdomen soon after surgery is practical and safe. It may help people with appendix or colon cancer that has spread within the abdomen (peritoneal carcinomatosis) by targeting cancer cells after tumor removal.
This Phase 1 trial tests a treatment that delivers heated chemotherapy directly into the abdomen (HIPEC) for certain cancers that have spread only within the abdominal lining. It aims to see how safely and effectively this approach works, especially when doctors can remove as much tumor as possible.
This Phase 2 study tests whether spraying chemotherapy into the abdomen (through a small procedure) after colon cancer surgery can lower the chance the cancer comes back. It is meant for people with high-risk tumor features but who have had surgery and have no proven relapse yet.
Hear when a new Peritoneal Carcinomatosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.